CDH17-Targeted Tumor-Killing Immunotherapeutics

CDH17-Targeted Tumor-Killing Immunotherapeutics

Safe: Our novel CAR technology will enable CAR T cells to specifically attack tumors and not normal tissues 
Effective: CDH17 is a tumor antigen abundant in cancer that has been shown to be effectively targeted in animal studies
Fast-Track Launch: CDH17-CAR T cells are expected to launch in Greater China markets late 2018

Solid tumors can be eliminated by CAR cells in the clinic; there has been recent success with CAR cell treatment of neuroblastoma (brain cancer). 

CDH17-CAR-T (Chimeric Antigen Receptor-T Cell)

CDH17-CAR-T (Chimeric Antigen Receptor-T cell)

Arbele is developing novel CAR-T cells targeting CDH17 antigen expressed on various cancer types including liver, stomach, colon, pancreas, esophagus and lung cancers

  1. High efficacy: One CAR-T cell can kill 100,000 cancer cells!
  2. Minor side effects

CDH17-CD3 BiTE (Bi-specific T Cell Engager)

CDH17-CD3 Bi-Specific MAbs (or BiTE)

BiTE (a trademark of Amgen) therapeutics, a bi-specific mAb that forms a link between tumor and T cells, causing cancer cell death

Proprietary and Technology Niche  

  • discovery of CDH17 cancer target (patent protected)
  • unique cancer target in liver, stomach, colon, pancreas and esophagus cancers (it has been shown to be effective in other cancer types)
  • development of CAR-T vector
  • CDH17 scFv engineering for bi-specific biologics and CAR-T cell development
  • development of drug candidates for other tumor-associated antigens

Chimeric Antigen Receptors (CAR-T)

Chimeric Antigen Receptor (CAR) technology directs T and NK (natural killer) cells to recognize cancer cells based on expression of specific cell surface proteins.

Bi-Specific Antibody (BiMAb)

The use of bispecific antibodies, targeting two tumor antigens for cancer treatment. This approach evolves to BiTE therapeutics, a bi-specific mAb that forms a link between tumor and T cells, causing cancer cell death.

Cancer Genome NGS (Big Data)

Using high-throughput and cutting-edge DNA sequencing technology, we can identify the oncogenes and mutations unique in patient's samples - tumor and liquid biopsies for early diagnosis and precision treatments.